Anti-Human CD279 (PD-1) (Nivolumab) Fc Muted
Product Sizes
100 µg
£760.00
12-8041-100UG
About this Product
- SKU:
- 12-8041
- Additional Names:
- PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1
- translate.label.attr.clone:
- 5C4.B8
- Clonality:
- Monoclonal
- Extra Details:
- Expression Host : HEK-293 Pathogen Testing : To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens; all of this recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Nivolumab. Clone 5C4.B8 binds to the extracellular portion of Human/Cynomolgus PD-1 and does not bind to other IgG superfamily proteins. This product is for research use only. Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers.1 PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.2 Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.3 Emerging research suggests that combined blockade of PD-1 and CTLA-4; with nivolumab and ipilimumab respectively; could produce greater antitumor activity than blockade of either pathway alone.4 This cost-effective; research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects.
- Host:
- Human
- Immunogen:
- Human PD-1
- Isotype:
- Human IgG1k
- Purification:
- >=95% monomer by analytical SEC
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- Functional grade biosimilar antibodies may be stored sterile as received at 2-8[o]C for up to one month. For longer term storage; aseptically aliquot in working volumes without diluting and store at -80[o]C. Avoid Repeated Freeze Thaw Cycles.
- Supplier:
- Abeomics
- Type:
- Antibodies:Monoclonal Antibody
- Manufacturer's Data Sheet:download_pdf.php
